Market Overview

Protagonist Therapeutics shares trading up 30.8% to $9.17 after final results from the company's PROPEL study supported further clinical development of PTG-100 for ulcerative colitis; The company also secured $22 million in equity financing.

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: WIIM Movers Trading Ideas

 

Related Articles (PTGX)

William Blair Upgrades Vital Therapies Ahead Of September Liver Failure Data

Turtle Beach Earnings Preview: Setting Up For A Short Squeeze?